Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 for acute RSV upper respiratory tract infection in ambulatory adults
NL-OMON49803Phase 2Withdrawn
- Sponsor
- Enanta Pharmaceuticals, Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and upper respiratory infection (URI) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Total symptom score area under the curve. Planned start Jul 2020; status: withdrawn.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)upper respiratory infection (URI)
Beyond the preview
Go deeper on NL-OMON49803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49803.